Clinical safety of ranibizumab in age-related macular degeneration
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
IMPORTANCE OF THE FIELD: Clinical safety of pharmaceutical products in the elderly is vital because of their increased risk of cardiac and other adverse events. AREAS COVERED IN THIS REVIEW: Search of the Medline database, including articles and abstracts from 1984 to 2009. WHAT THE READER WILL GAIN: Knowledge of ocular and systemic risks: The rate of endophthalmitis was 0.05% per injection (MARINA) and <0.1% per injection (ANCHOR), rates confirmed in a retrospective analysis of 14,320 injections. Moderate increases in intraocular pressure were transient, and incidences of intraocular inflammation were rarely serious. Systemic arterial thromboembolic events occurred in 4.6 and 0% of ranibizumab-treated patients and in 3.8 and 0% of sham-treated patients in MARINA (2 years) and PIER (1 year), respectively. In SAILOR, there was a numerically higher rate of cerebrovascular stroke with 0.5 mg ranibizumab compared with 0.3 mg ranibizumab (1.2 vs 0.7%), which was a non-statistically significant trend in patients with a history of stroke. TAKE HOME MESSAGE: Although further studies to investigate the risk of stroke with ranibizumab therapy are required, repeated intravitreal ranibizumab was well tolerated and not associated with clinically significant safety risks during up to 2 years of treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522 · cited 9×
“Brown, 2006 [18] ANCHOR (1 year) Any arterial thromboembolic event* PDT: 3/143 (2.”
BackgroundMethodInfluentialBrown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.018 · Cited by 1,318
Prevalence of age-related maculopathy in Australia
Mitchell, P., Smith, W., Attebo, K., & Wang, J. J. (1995) · Ophthalmology · doi:10.1016/s0161-6420(95)30846-9 · Cited by 1,062
Regillo, C. D., Brown, D. M., Abraham, P., Yue, H., Ianchulev, T., Schneider, S., & Shams, N. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.10.004 · Cited by 858
The Natural History and Prognosis of Neovascular Age-Related Macular Degeneration
Wong, T., Chakravarthy, U., Klein, R., Mitchell, P., Zlateva, G., Buggage, R., Fahrbach, K., Probst, C., & Sledge, I. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2007.03.008 · Cited by 601 · cited 1×
“Although some data suggest that classic CNV may be associated with a worse prognosis than occult CNV [6-8], a systematic review of 53 studies concluded that it was not possible to attribute different prognoses to subtypes of neovascular AMD [9].”
BackgroundRisk factors for neovascular age-related macular degeneration
(1992) · Archives of Ophthalmology · doi:10.1001/archopht.1992.01080240041025 · Cited by 486
Heier, J. S. (2006) · Archives of Ophthalmology · doi:10.1001/archopht.124.11.1532 · Cited by 304 · cited 18×
“A protocol amendment increased the interval between ranibizumab injection and verteporfin PDT from 7 days to 28 days and no further serious ocular inflammation was subsequently reported [30].”
BackgroundMethodResultInfluentialCigarette Smoking and Age-Related Macular Degeneration in the EUREYE Study
Chakravarthy, U., Augood, C., Bentham, G. C., de Jong, P. T. V. M., Rahu, M., Seland, J., Soubrane, G., Tomazzoli, L., Topouzis, F., Vingerling, J. R., et al. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2006.09.022 · Cited by 230 · cited 1×
“AMD and cardiovascular disease have a number of risk factors in common, including age and smoking [71].”
BackgroundNatural course of poorly defined choroidal neovascularization associated with macular degeneration
Bressler, N. M. (1988) · Archives of Ophthalmology · doi:10.1001/archopht.1988.01060140705039 · Cited by 165 · cited 1×
“Although some data suggest that classic CNV may be associated with a worse prognosis than occult CNV [6-8], a systematic review of 53 studies concluded that it was not possible to attribute different prognoses to subtypes of neovascular AMD [9].”
BackgroundAge-Related Macular Degeneration and Risk of Coronary Heart Disease
Wong, T. Y., Tikellis, G., Sun, C., Klein, R., Couper, D. J., & Sharrett, A. R. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2006.06.039 · Cited by 123
Cited by
Ghasemi Falavarjani, K., & Nguyen, Q. D. (2013) · Eye · doi:10.1038/eye.2013.107 · Cited by 982
Rakoczy, E. P., Lai, C.-M., Magno, A. L., Wikstrom, M. E., French, M. A., Pierce, C. M., Schwartz, S. D., Blumenkranz, M. S., Chalberg, T. W., Degli-Esposti, M. A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00345-1 · Cited by 189
Mitchell, P. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.585394 · Cited by 102
Metadata
- Authors
- Schmidt-Erfurth, U.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa Healthcare
- Published
- 2009-12-15
- Volume
- 9
- Issue
- 1
- Pages
- 149-165
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W2043557241
- Cited by
- 51
- References
- 11
- FWCI
- 8.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical safety of ranibizumab in age-related macular degeneration. https://app.cochat.ai/papers/10.1517/14740330903418422
- The paper
- Schmidt-Erfurth, U. (2010). Clinical safety of ranibizumab in age-related macular degeneration. Expert Opinion on Drug Safety. https://doi.org/10.1517/14740330903418422
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.